Top Suppliers:I want be here
  • DC Chemicals Limited
  • China
  • Product Name: Safinamide
  • Price: $400.0/100mg $700.0/250mg $1300.0/1g
  • Purity: 98.0%
  • Stocking Period: 3 Day
  • Contact: Tony Cao

133865-89-1

133865-89-1 structure
133865-89-1 structure
  • Name: Safinamide
  • Chemical Name: (2S)-2-[[4-[(3-fluorophenyl)methoxy]phenyl]methylamino]propanamide
  • CAS Number: 133865-89-1
  • Molecular Formula: C17H19FN2O2
  • Molecular Weight: 302.343
  • Catalog: Biochemical Inhibitor Metabolism MAO inhibitor
  • Create Date: 2018-04-03 08:00:00
  • Modify Date: 2024-01-09 06:48:28
  • Safinamide (EMD 1195686; FCE 26743) selectively and reversibly inhibits MAO-B with IC50 of 98 nM, exhibits 5918-fold selectivity against MAO-A.IC50 value: 98 nM [1]Target: MAO-BSafinamide (EMD 1195686; FCE 26743; ) is a highly selective and reversible monoamine oxidase type B (MAO-B) inhibitor that increases neostriatal dopamine concentration. In addition, Safinamide (EMD 1195686; FCE 26743; ) is voltage-dependent sodium and calcium channel blocker. Safinamide (EMD 1195686; FCE 26743; ) appears to bind to the batrachotoxin-sensitive site 2 of the voltage-sensitive sodium channels. Safinamide blocks N and L-type calcium channels and inhibits glutamate and aspartate release from synaptic terminals.

Name (2S)-2-[[4-[(3-fluorophenyl)methoxy]phenyl]methylamino]propanamide
Synonyms (S)-(+)-2-[4-(3-fluorobenzyloxy)benzylamino]-propanamide
(2S)-2-[4-(3-fluorobenzyloxy)benzylamino]propionamide
Safinamide
N-{4-[(3-Fluorobenzyl)oxy]benzyl}-L-alaninamide
(2S)-2-[[[4-[(3-Fluorophenyl)methoxy]phenyl]methyl]amino]propanamide
(S)-2-[[4-[(3-Fluorobenzyl)oxy]benzyl]amino]propionamide
ZVY1&M1R DO1R CF &&L or S Form
Propanamide, 2-[[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]amino]-, (2S)-
Description Safinamide (EMD 1195686; FCE 26743) selectively and reversibly inhibits MAO-B with IC50 of 98 nM, exhibits 5918-fold selectivity against MAO-A.IC50 value: 98 nM [1]Target: MAO-BSafinamide (EMD 1195686; FCE 26743; ) is a highly selective and reversible monoamine oxidase type B (MAO-B) inhibitor that increases neostriatal dopamine concentration. In addition, Safinamide (EMD 1195686; FCE 26743; ) is voltage-dependent sodium and calcium channel blocker. Safinamide (EMD 1195686; FCE 26743; ) appears to bind to the batrachotoxin-sensitive site 2 of the voltage-sensitive sodium channels. Safinamide blocks N and L-type calcium channels and inhibits glutamate and aspartate release from synaptic terminals.
Related Catalog
References

[1]. Leonetti F, et al. Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoamine oxidase. J Med Chem, 2007, 50(20), 4909-4916.

[2]. Schapira AH. Safinamide in the treatment of Parkinson's disease. Expert Opin Pharmacother. 2010 Sep;11(13):2261-8.

[3]. Onofrj M, et al. An expert opinion on safinamide in Parkinson's disease. Expert Opin Investig Drugs. 2008 Jul;17(7):1115-25.

[4]. Chazot PL. Safinamide for the treatment of Parkinson's disease, epilepsy and restless legs syndrome. Curr Opin Investig Drugs. 2007 Jul;8(7):570-9.

[5]. Dal Bo L, et al. Bioassay of safinamide in biological fluids of humans and various animal species. Arzneimittelforschung. 2006;56(12):814-9. http://www.ncbi.nlm.nih.gov/pubmed/17260668

Density 1.2±0.1 g/cm3
Boiling Point 476.7±40.0 °C at 760 mmHg
Melting Point 208-212°
Molecular Formula C17H19FN2O2
Molecular Weight 302.343
Flash Point 242.1±27.3 °C
Exact Mass 302.143066
PSA 64.35000
LogP 2.37
Vapour Pressure 0.0±1.2 mmHg at 25°C
Index of Refraction 1.570
Hazard Codes Xi
RTECS TX1457385

~87%

133865-89-1 structure

133865-89-1

Literature: NEWRON PHARMACEUTICALS S.P.A. Patent: WO2009/74478 A1, 2009 ; Location in patent: Page/Page column 60-62 ;

~92%

133865-89-1 structure

133865-89-1

Literature: NEWRON PHARMACEUTICALS S.P.A. Patent: WO2007/147491 A1, 2007 ; Location in patent: Page/Page column 34-35 ;

~89%

133865-89-1 structure

133865-89-1

Literature: NEWRON PHARMACEUTICALS S.P.A. Patent: WO2007/147491 A1, 2007 ; Location in patent: Page/Page column 32 ;

~%

133865-89-1 structure

133865-89-1

Literature: WO2009/74478 A1, ; Page/Page column 71-72 ;

~%

133865-89-1 structure

133865-89-1

Literature: WO2009/74478 A1, ; Page/Page column 64-65 ;

~%

133865-89-1 structure

133865-89-1

Literature: Journal of Medicinal Chemistry, , vol. 50, # 20 p. 4909 - 4916